Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Blood (2019) 134 (Supplement_1): 661.

https://doi.org/10.1182/blood-2019-126767

Published: 2019

Journal Articles

Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study

Blood (2018) 132 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2018-99-117028

Published: 2018

Journal Articles

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Simona Soverini, PhD, Luana Bavaro, Margherita Martelli, Caterina De Benedittis, PhD, Alessandra Iurlo, Nicola Orofino, MD, Livio Pagano, Marianna Criscuolo, Massimiliano Bonifacio, Luigi Scaffidi, MD, Simona Sica, MD, Federica Sorà, MD, Elena Maino, Michela Rondoni, MD, Maria Antonella Laginestra, PhD, Francesca Lunghi, Anna Ermacora, Mariella D'adda, MD, Gabriele Gugliotta, MD PhD, Fausto Castagnetti, Gianantonio Rosti, Cristina Papayannidis, Giovanni Marconi, Antonio Curti, Maria Cristina Miggiano, Sara Galimberti, Antonio Percesepe, MD PhD, Fabio Stagno, Rosaria Sancetta, MD, Mario Annunziata, Franca Falzetti, MD, Isabella Capodanno, Patrizia Pregno, Margherita Maffioli, MD, Tamara Intermesoli, MD, Eros Di Bona, MD, Giovanni Caocci, MD, Imma Attolico, MD, Gianni Binotto, Monica Bocchia, MD PhD, Emanuele Angelucci, MD, Nicola Sgherza, MD, Luigiana Luciano, Flavio Mignone, Stefano A. Pileri, MD PhD, Giovanni Martinelli, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 789.

https://doi.org/10.1182/blood-2018-99-117166

Published: 2018

Journal Articles

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Simona Soverini, PhD, Luana Bavaro, Caterina De Benedittis, PhD, Margherita Martelli, Stefania Stella, PhD, Paolo Vigneri, MD PhD, Alessandra Iurlo, MD PhD, Nicola Orofino, MD, Simona Sica, MD, Federica Sorà, MD, Sara Galimberti, PhD MD, Claudia Baratè, MD PhD, Francesco Albano, MD, Antonella Russo Rossi, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Fausto Castagnetti, MD, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Fabio Stagno, MD PhD, Elisabetta Novella, PhD, Eros Di Bona, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD PhD, Marzia Salvucci, MD, Mariella D'Adda, MD, Rosaria Sancetta, MD, Elisabetta Calistri, MD, Monica Bocchia, Isabella Capodanno, MD, Giuseppina Spinosa, MD, Maria Antonella Laginestra, PhD, Santa Errichiello, PhD, Anna Serra, Dr, Francesca Carnuccio, Dr, Sabrina Coluzzi, PhD, Mario Annunziata, MD, Caterina Musolino, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD PhD, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 248.

https://doi.org/10.1182/blood.V130.Suppl_1.248.248

Published: 2017

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Blood (2016) 128 (22): 3136.

https://doi.org/10.1182/blood.V128.22.3136.3136

Published: 2016

Journal Articles

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Blood (2016) 128 (22): 5191.

https://doi.org/10.1182/blood.V128.22.5191.5191

Published: 2016

Journal Articles

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Blood (2015) 126 (23): 4085.

https://doi.org/10.1182/blood.V126.23.4085.4085

Published: 2015

Journal Articles

Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

Manuela Mancini, PhD, Simona Soverini, Elisa Leo, PhD, Fausto Castagnetti, PhD, Caterina De Benedittis, PhD, Gabriele Gugliotta, PhD, Gianantonio Rosti, MD, Maria Alessandra Santucci, MD, Michele Cavo, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 1573.

https://doi.org/10.1182/blood.V126.23.1573.1573

Published: 2015

Journal Articles

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Blood (2015) 126 (23): 346.

https://doi.org/10.1182/blood.V126.23.346.346

Published: 2015

Journal Articles

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Simona Soverini, PhD, Caterina De Benedittis, PhD, Claudia Venturi, PhD, Cristina Papayannidis, MD PhD, Manuela Mancini, PhD, Katerina Machova Polakova, Domenico Russo, MD PhD, Paola Bresciani, MD, Alessandra Iurlo, MD PhD, Elisabetta Abruzzese, MD, Federica Sorà, MD PhD, Michele Baccarani, Michele Cavo, MD, Torsten Haferlach, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2489.

https://doi.org/10.1182/blood.V126.23.2489.2489

Published: 2015

Journal Articles

Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing

Simona Soverini, PhD, Caterina De Benedittis, Cristina Papayannidis, MD, Luca Zazzeroni, Claudia Venturi, PhD, Ilaria Iacobucci, PhD, Domenico Russo, MD PhD, Paola Bresciani, Mario Luppi, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 2259.

https://doi.org/10.1182/blood.V124.21.2259.2259

Published: 2014

Journal Articles

A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis

Blood (2014) 124 (21): 3188.

https://doi.org/10.1182/blood.V124.21.3188.3188

Published: 2014

Journal Articles

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

Elisa Leo, PhD, Giorgia Simonetti, PhD, Manuela Mancini, PhD, Nevena Veljkovic, PhD, Virginia Campi, Fausto Castagnetti, MD, Gabriele Gugliotta, MD, Caterina De Benedittis, Maria Alessandra Santucci, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 3125.

https://doi.org/10.1182/blood.V124.21.3125.3125

Published: 2014

Journal Articles

In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants

Blood (2014) 124 (21): 815.

https://doi.org/10.1182/blood.V124.21.815.815

Published: 2014

Journal Articles

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Maria Teresa Bochicchio, Barbara Izzo, Enrico Gottardi, Biagio De Angelis, Roberta Lorenzatti, Claudia Venturi, Francesca Crasto, Caterina De Benedittis, Filomena Daraio, Emanuela Ottaviani, Alessandro Volpengo, Giuseppe Saglio, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 1809.

https://doi.org/10.1182/blood.V124.21.1809.1809

Published: 2014

Journal Articles

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Blood (2014) 124 (21): 1856.

https://doi.org/10.1182/blood.V124.21.1856.1856

Published: 2014

Journal Articles

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Blood (2014) 124 (21): 1881.

https://doi.org/10.1182/blood.V124.21.1881.1881

Published: 2014

Journal Articles

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Blood (2013) 122 (21): 3911.

https://doi.org/10.1182/blood.V122.21.3911.3911

Published: 2013

NARROW

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing

A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis

FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia

In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only